Search

Your search keyword '"Petersen, Eefke J"' showing total 199 results
Start Over Author "Petersen, Eefke J"
199 results on '"Petersen, Eefke J"'

1. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis

Author

Admiraal, Rick, Nierkens, Stefan, de Witte, Moniek A, Petersen, Eefke J, Fleurke, Ger-jan, Verrest, Luka, Belitser, Svetlana V, Bredius, Robbert G M, Raymakers, Reinier A P, Knibbe, Catherijne A J, Minnema, Monique C, van Kesteren, Charlotte, Kuball, Jurgen, and Boelens, Jaap J

Published
2017
Full Text
View/download PDF

2. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., primary, Gini, Andrea, primary, Rigter, Lisanne S., primary, Spaander, Manon C.W., primary, Moons, Leon M.G., primary, Bisseling, Tanya M., primary, de Boer, Jan Paul, primary, Verbeek, Wieke H.M., primary, Lugtenburg, Pieternella J., primary, Janus, Cecile P.M., primary, Petersen, Eefke J., primary, Roesink, Judith M., primary, van der Maazen, Richard W.M., primary, Aleman, Berthe M.P., primary, Meijer, Gerrit A., primary, van Leeuwen, Flora E., primary, Snaebjornsson, Petur, primary, Carvalho, Beatriz, primary, van Leerdam, Monique E., primary, and Lansdorp-Vogelaar, Iris, primary

Published
2023
Full Text
View/download PDF

3. Supplementary Figure from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., primary, Gini, Andrea, primary, Rigter, Lisanne S., primary, Spaander, Manon C.W., primary, Moons, Leon M.G., primary, Bisseling, Tanya M., primary, de Boer, Jan Paul, primary, Verbeek, Wieke H.M., primary, Lugtenburg, Pieternella J., primary, Janus, Cecile P.M., primary, Petersen, Eefke J., primary, Roesink, Judith M., primary, van der Maazen, Richard W.M., primary, Aleman, Berthe M.P., primary, Meijer, Gerrit A., primary, van Leeuwen, Flora E., primary, Snaebjornsson, Petur, primary, Carvalho, Beatriz, primary, van Leerdam, Monique E., primary, and Lansdorp-Vogelaar, Iris, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Data from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., primary, Gini, Andrea, primary, Rigter, Lisanne S., primary, Spaander, Manon C.W., primary, Moons, Leon M.G., primary, Bisseling, Tanya M., primary, de Boer, Jan Paul, primary, Verbeek, Wieke H.M., primary, Lugtenburg, Pieternella J., primary, Janus, Cecile P.M., primary, Petersen, Eefke J., primary, Roesink, Judith M., primary, van der Maazen, Richard W.M., primary, Aleman, Berthe M.P., primary, Meijer, Gerrit A., primary, van Leeuwen, Flora E., primary, Snaebjornsson, Petur, primary, Carvalho, Beatriz, primary, van Leerdam, Monique E., primary, and Lansdorp-Vogelaar, Iris, primary

Published
2023
Full Text
View/download PDF

5. Data from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., primary, Gini, Andrea, primary, Rigter, Lisanne S., primary, Spaander, Manon C.W., primary, Moons, Leon M.G., primary, Bisseling, Tanya M., primary, de Boer, Jan Paul, primary, Verbeek, Wieke H.M., primary, Lugtenburg, Pieternella J., primary, Janus, Cecile P.M., primary, Petersen, Eefke J., primary, Roesink, Judith M., primary, van der Maazen, Richard W.M., primary, Aleman, Berthe M.P., primary, Meijer, Gerrit A., primary, van Leeuwen, Flora E., primary, Snaebjornsson, Petur, primary, Carvalho, Beatriz, primary, van Leerdam, Monique E., primary, and Lansdorp-Vogelaar, Iris, primary

Published
2023
Full Text
View/download PDF

6. Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma

Author

MS Hematologie, Regenerative Medicine and Stem Cells, Cancer, de Vries, Simone, Haaksma, Miriam L, Jóźwiak, Katarzyna, Schaapveld, Michael, Hodgson, David C, Lugtenburg, Pieternella J, Krol, Augustinus D G, Petersen, Eefke J, van Spronsen, Dick Johan, Ahmed, Sameera, Hauptmann, Michael, Aleman, Berthe M P, van Leeuwen, Flora E, MS Hematologie, Regenerative Medicine and Stem Cells, Cancer, de Vries, Simone, Haaksma, Miriam L, Jóźwiak, Katarzyna, Schaapveld, Michael, Hodgson, David C, Lugtenburg, Pieternella J, Krol, Augustinus D G, Petersen, Eefke J, van Spronsen, Dick Johan, Ahmed, Sameera, Hauptmann, Michael, Aleman, Berthe M P, and van Leeuwen, Flora E

Published
2023

7. Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma

Author

de Vries, Simone, primary, Haaksma, Miriam L., additional, Jóźwiak, Katarzyna, additional, Schaapveld, Michael, additional, Hodgson, David C., additional, Lugtenburg, Pieternella J., additional, Krol, Augustinus D.G., additional, Petersen, Eefke J., additional, van Spronsen, Dick Johan, additional, Ahmed, Sameera, additional, Hauptmann, Michael, additional, Aleman, Berthe M.P., additional, and van Leeuwen, Flora E., additional

Published
2023
Full Text
View/download PDF

8. Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., Gini, Andrea, Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., de Boer, Jan Paul, Verbeek, Wieke H.M., Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Aleman, Berthe M.P., Meijer, Gerrit A., van Leeuwen, Flora E., Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E., Lansdorp-Vogelaar, Iris, Ykema, Berbel L.M., Gini, Andrea, Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., de Boer, Jan Paul, Verbeek, Wieke H.M., Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Aleman, Berthe M.P., Meijer, Gerrit A., van Leeuwen, Flora E., Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E., and Lansdorp-Vogelaar, Iris

Abstract

Background: Hodgkin lymphoma survivors treated with infradiaphragmatic radiotherapy (IRT) and/or procarbazine have an increased risk of developing colorectal cancer. We investigated the cost-effectiveness of colorectal cancer surveillance in Dutch Hodgkin lymphoma survivors to determine the optimal surveillance strategy for different Hodgkin lymphoma subgroups. Methods: The Microsimulation Screening Analysis-Colon model was adjusted to reflect colorectal cancer and other-cause mortality risk in Hodgkin lymphoma survivors. Ninety colorectal cancer surveillance strategies were evaluated varying in starting and stopping age, interval, and modality [colonoscopy, fecal immunochemical test (FIT, OC-Sensor; cutoffs: 10/20/47 mg Hb/g feces), and multi-target stool DNA test (Cologuard)]. Analyses were also stratified per primary treatment (IRT and procarbazine or procarbazine without IRT). Colorectal cancer deaths averted (compared with no surveillance) and incremental cost-effectiveness ratios (ICER) were primary outcomes. The optimal surveillance strategy was identified assuming a willingness-to-pay threshold of €20,000 per life-years gained (LYG). Results: Overall, the optimal surveillance strategy was annual FIT (47 mg) from age 45 to 70 years, which might avert 70% of colorectal cancer deaths in Hodgkin lymphoma survivors (compared with no surveillance; ICER:€18,000/LYG). The optimal surveillance strategy in Hodgkin lymphoma survivors treated with procarbazine without IRT was biennial FIT (47 mg) from age 45 to 70 years (colorectal cancer mortality averted 56%; ICER:€15,000/LYG), and when treated with IRT and procarbazine, annual FIT (47 mg) surveillance from age 40 to 70 was most cost-effective (colorectal cancer mortality averted 75%; ICER:€13,000/LYG). Conclusions: Colorectal cancer surveillance in Hodgkin lymphoma survivors is cost-effective and should commence earlier than screening occurs in population screening programs. For all subgroups, FIT surveillance was

Published
2022

9. Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin’s lymphoma survivors

Author

Ykema, Berbel L.M., Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., Aleman, Berthe M.P., Dekker, Evelien, Verbeek, Wieke H.M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, Snaebjornsson, Petur, van Leerdam, Monique E., Ykema, Berbel L.M., Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., Aleman, Berthe M.P., Dekker, Evelien, Verbeek, Wieke H.M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, Snaebjornsson, Petur, and van Leerdam, Monique E.

Abstract

Background: Hodgkin’s lymphoma (HL) survivors treated with abdominal radiotherapy and/or procarbazine have an increased risk of developing colorectal neoplasia. Aims: We evaluated the clinicopathological characteristics and risk factors for developing (advanced) neoplasia (AN) in HL survivors. Methods: In all, 101 HL survivors (median age 51 years, median age of HL diagnosis 25 years) underwent colonoscopy and 350 neoplasia and 44 AN (classified as advanced adenomas/serrated lesions or colorectal cancer), mostly right-sided, were detected, as published previously. An average-risk asymptomatic cohort who underwent screening colonoscopy were controls (median age 60 years). Clinicopathological characteristics of AN were evaluated in both groups. Mismatch repair (MMR) status was assessed using immunohistochemistry (MLH1/MSH2/MSH6/PMS2). Logistic regression analysis was performed to evaluate the risk factors for AN in HL survivors, including age at HL diagnosis and interval between HL and colonoscopy. Results: In 101 colonoscopies in HL survivors, AN was primarily classified based on polyp size ≥10 mm, whereas (high-grade)dysplasia was more often seen in AN in controls. An interval between HL diagnosis and colonoscopy >26 years was associated with more AN compared with an interval of <26 years, with an odds ratio for AN of 3.8 (95% confidence interval 1.4–9.1) (p < 0.01). All 39 AN that were assessed were MMR proficient. Conclusions: Colorectal neoplasia in HL survivors differ from average-risk controls; classification AN was primarily based on polyp size (≥10 mm) in HL survivors. Longer follow-up between HL diagnosis and colonoscopy was associated with a higher prevalence of AN in HL survivors.

Published
2022

10. Cost-effectiveness of colorectal cancer surveillance in Hodgkin lymphoma survivors treated with procarbazine and/or infradiaphragmatic radiotherapy

Author

MS MDL 1, Cancer, MS Hematologie, Regenerative Medicine and Stem Cells, MS Radiotherapie, Pathologie Groep Van Diest, Ykema, Berbel Lm, Gini, Andrea, Rigter, Lisanne S, Spaander, Manon Cw, Moons, Leon Mg, Bisseling, Tanya M, de Boer, Jan Paul, Verbeek, Wieke Hm, Lugtenburg, Pieternella J, Janus, Cecile Pm, Petersen, Eefke J, Roesink, Judith M, van der Maazen, Richard W M, Aleman, Berthe Mp, Meijer, Gerrit A, Van Leeuwen, Flora E, Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E, Lansdorp-Vogelaar, Iris, MS MDL 1, Cancer, MS Hematologie, Regenerative Medicine and Stem Cells, MS Radiotherapie, Pathologie Groep Van Diest, Ykema, Berbel Lm, Gini, Andrea, Rigter, Lisanne S, Spaander, Manon Cw, Moons, Leon Mg, Bisseling, Tanya M, de Boer, Jan Paul, Verbeek, Wieke Hm, Lugtenburg, Pieternella J, Janus, Cecile Pm, Petersen, Eefke J, Roesink, Judith M, van der Maazen, Richard W M, Aleman, Berthe Mp, Meijer, Gerrit A, Van Leeuwen, Flora E, Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E, and Lansdorp-Vogelaar, Iris

Published
2022

11. Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin’s lymphoma survivors

Author

MS MDL 1, Cancer, MS Hematologie, Regenerative Medicine and Stem Cells, MS Radiotherapie, Pathologie Algemene Pat.zorg, Pathologie Groep Van Diest, Ykema, Berbel L.M., Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., Aleman, Berthe M.P., Dekker, Evelien, Verbeek, Wieke H.M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, Snaebjornsson, Petur, van Leerdam, Monique E., MS MDL 1, Cancer, MS Hematologie, Regenerative Medicine and Stem Cells, MS Radiotherapie, Pathologie Algemene Pat.zorg, Pathologie Groep Van Diest, Ykema, Berbel L.M., Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., Aleman, Berthe M.P., Dekker, Evelien, Verbeek, Wieke H.M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, Snaebjornsson, Petur, and van Leerdam, Monique E.

Published
2022

12. Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy.

Author

Ykema, Berbel L. M., Gini, Andrea, Rigter, Lisanne S., Spaander, Manon C. W., Moons, Leon M. G., Bisseling, Tanya M., de Boer, Jan Paul, Verbeek, Wieke H. M., Lugtenburg, Pieternella J., Janus, Cecile P. M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W. M., Aleman, Berthe M. P., Meijer, Gerrit A., van Leeuwen, Flora E., Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E., and Lansdorp-Vogelaar, Iris

Abstract

Background: Hodgkin lymphoma survivors treated with infradiaphragmatic radiotherapy (IRT) and/or procarbazine have an increased risk of developing colorectal cancer. We investigated the cost-effectiveness of colorectal cancer surveillance in Dutch Hodgkin lymphoma survivors to determine the optimal surveillance strategy for different Hodgkin lymphoma subgroups. Methods: The Microsimulation Screening Analysis-Colon model was adjusted to reflect colorectal cancer and other-cause mortality risk in Hodgkin lymphoma survivors. Ninety colorectal cancer surveillance strategies were evaluated varying in starting and stopping age, interval, and modality [colonoscopy, fecal immunochemical test (FIT, OC-Sensor; cutoffs: 10/20/47 µg Hb/g feces), and multi-target stool DNA test (Cologuard)]. Analyses were also stratified per primary treatment (IRT and procarbazine or procarbazine without IRT). Colorectal cancer deaths averted (compared with no surveillance) and incremental cost-effectiveness ratios (ICER) were primary outcomes. The optimal surveillance strategy was identified assuming a willingness-to-pay threshold of €20,000 per life-years gained (LYG). Results: Overall, the optimal surveillance strategy was annual FIT (47 µg) from age 45 to 70 years, which might avert 70% of colorectal cancer deaths in Hodgkin lymphoma survivors (compared with no surveillance; ICER:€18,000/LYG). The optimal surveillance strategy in Hodgkin lymphoma survivors treated with procarbazine without IRT was biennial FIT (47 µg) from age 45 to 70 years (colorectal cancer mortality averted 56%; ICER:€15,000/LYG), and when treated with IRT and procarbazine, annual FIT (47 µg) surveillance from age 40 to 70 was most cost-effective (colorectal cancer mortality averted 75%; ICER:€13,000/LYG). Conclusions: Colorectal cancer surveillance in Hodgkin lymphoma survivors is cost-effective and should commence earlier than screening occurs in population screening programs. For all subgroups, FIT surveillance was the most cost-effective strategy. Impact: Colorectal cancer surveillance should be implemented in Hodgkin lymphoma survivors. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

13. Second Cancer Risk Up to 40 Years after Treatment for Hodgkinʼs Lymphoma

Author

Schaapveld, Michael, Aleman, Berthe M.P., van Eggermond, Anna M., Janus, Cécile P.M., Krol, Augustinus D.G., van der Maazen, Richard W.M., Roesink, Judith, Raemaekers, John M.M., de Boer, Jan Paul, Zijlstra, Josée M., van Imhoff, Gustaaf W., Petersen, Eefke J., Poortmans, Philip M.P., Beijert, Max, Lybeert, Marnix L., Mulder, Ina, Visser, Otto, Louwman, Marieke W.J., Krul, Inge M., Lugtenburg, Pieternella J., and van Leeuwen, Flora E.

Published
2015
Full Text
View/download PDF

16. Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin’s lymphoma survivors

Author

Ykema, Berbel L. M., primary, Rigter, Lisanne S., additional, Spaander, Manon C. W., additional, Moons, Leon M. G., additional, Bisseling, Tanya M., additional, Aleman, Berthe M. P., additional, Dekker, Evelien, additional, Verbeek, Wieke H. M., additional, Kuipers, Ernst J., additional, Boer, Jan Paul, additional, Lugtenburg, Pieternella J., additional, Janus, Cecile P. M., additional, Petersen, Eefke J., additional, Roesink, Judith M., additional, Maazen, Richard W. M., additional, Meijer, Gerrit A., additional, Schaapveld, Michael, additional, Leeuwen, Flora E., additional, Carvalho, Beatriz, additional, Snaebjornsson, Petur, additional, and Leerdam, Monique E., additional

Published
2021
Full Text
View/download PDF

17. Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients

Author

de Vries, Simone, Schaapveld, Michael, Janus, Cécile P.M., Daniëls, Laurien A., Petersen, Eefke J., van der Maazen, Richard W.M., Zijlstra, Josée M., Beijert, Max, Nijziel, Marten R., Verschueren, Karijn M.S., Kremer, Leontien C.M., van Eggermond, Anna M., Lugtenburg, Pieternella J., Krol, Augustinus D.G., Roesink, Judith M., Plattel, Wouter J., van Spronsen, Dick Johan, van Imhoff, Gustaaf W., de Boer, Jan Paul, Aleman, Berthe M.P., van Leeuwen, Flora E., de Vries, Simone, Schaapveld, Michael, Janus, Cécile P.M., Daniëls, Laurien A., Petersen, Eefke J., van der Maazen, Richard W.M., Zijlstra, Josée M., Beijert, Max, Nijziel, Marten R., Verschueren, Karijn M.S., Kremer, Leontien C.M., van Eggermond, Anna M., Lugtenburg, Pieternella J., Krol, Augustinus D.G., Roesink, Judith M., Plattel, Wouter J., van Spronsen, Dick Johan, van Imhoff, Gustaaf W., de Boer, Jan Paul, Aleman, Berthe M.P., and van Leeuwen, Flora E.

Abstract

BACKGROUND: Few studies have examined the impact of treatment-related morbidity on long-term, cause-specific mortality in Hodgkin lymphoma (HL) patients. METHODS: This multicenter cohort included 4919 HL patients, treated before age 51 years between 1965 and 2000, with a median follow-up of 20.2 years. Standardized mortality ratios, absolute excess mortality (AEM) per 10 000 person-years, and cause-specific cumulative mortality by stage and primary treatment, accounting for competing risks, were calculated. RESULTS: HL patients experienced a 5.1-fold (AEM = 123 excess deaths per 10 000 person-years) higher risk of death due to causes other than HL. This risk remained increased in 40-year survivors (standardized mortality ratio = 5.2, 95% confidence interval [CI] = 4.2 to 6.5, AEM = 619). At age 54 years, HL survivors experienced similar cumulative mortality (20.0%) from causes other than HL to 71-year-old individuals from the general population. Whereas HL mortality statistically significantly decreased over the calendar period (P < .001), solid tumor mortality did not change in the most recent treatment era. Patients treated in 1989-2000 had lower 25-year cardiovascular disease mortality than patients treated in 1965-1976 (4.3% vs 5.7%; subdistribution hazard ratio = 0.65, 95% CI = 0.46 to 0.93). Infectious disease mortality was not only increased after splenectomy but also after spleen irradiation (hazard ratio = 2.81, 95% CI = 1.55 to 5.07). For stage I-II, primary treatment with chemotherapy (CT) alone was associated with statistically significantly higher HL mortality (P < .001 for CT vs radiotherapy [RT]; P = .04 for CT vs RT+CT) but lower 30-year mortality from causes other than HL (15.8%, 95% CI = 9.7% to 23.3%) compared with RT alone (36.9%, 95% CI = 34.0% to 39.8%, P = .001) and RT and CT combined (29.8%, 95% CI = 26.8% to 32.9%, P = .02). CONCLUSIONS: Compared with the general population, HL survivors have a su

Published
2021

18. Long-term cause-specific mortality in hodgkin lymphoma patients

Author

MS Hematologie, Regenerative Medicine and Stem Cells, Cancer, MS Radiotherapie, de Vries, Simone, Schaapveld, Michael, Janus, Cécile P M, Daniëls, Laurien A, Petersen, Eefke J, van der Maazen, Richard W M, Zijlstra, Josée M, Beijert, Max, Nijziel, Marten R, Verschueren, Karijn M S, Kremer, Leontien C M, van Eggermond, Anna M, Lugtenburg, Pieternella J, Krol, Augustinus D G, Roesink, Judith M, Plattel, Wouter J, van Spronsen, Dick Johan, van Imhoff, Gustaaf W, de Boer, Jan Paul, Aleman, Berthe M P, van Leeuwen, Flora E, MS Hematologie, Regenerative Medicine and Stem Cells, Cancer, MS Radiotherapie, de Vries, Simone, Schaapveld, Michael, Janus, Cécile P M, Daniëls, Laurien A, Petersen, Eefke J, van der Maazen, Richard W M, Zijlstra, Josée M, Beijert, Max, Nijziel, Marten R, Verschueren, Karijn M S, Kremer, Leontien C M, van Eggermond, Anna M, Lugtenburg, Pieternella J, Krol, Augustinus D G, Roesink, Judith M, Plattel, Wouter J, van Spronsen, Dick Johan, van Imhoff, Gustaaf W, de Boer, Jan Paul, Aleman, Berthe M P, and van Leeuwen, Flora E

Published
2021

22. Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients

Author

de Vries, Simone, primary, Schaapveld, Michael, additional, Janus, Cécile P M, additional, Daniëls, Laurien A, additional, Petersen, Eefke J, additional, van der Maazen, Richard W M, additional, Zijlstra, Josée M, additional, Beijert, Max, additional, Nijziel, Marten R, additional, Verschueren, Karijn M S, additional, Kremer, Leontien C M, additional, van Eggermond, Anna M, additional, Lugtenburg, Pieternella J, additional, Krol, Augustinus D G, additional, Roesink, Judith M, additional, Plattel, Wouter J, additional, van Spronsen, Dick Johan, additional, van Imhoff, Gustaaf W, additional, de Boer, Jan Paul, additional, Aleman, Berthe M P, additional, and van Leeuwen, Flora E, additional

Published
2020
Full Text
View/download PDF

23. Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin's lymphoma survivors.

Author

Ykema, Berbel L. M., Rigter, Lisanne S., Spaander, Manon C. W., Moons, Leon M. G., Bisseling, Tanya M., Aleman, Berthe M. P., Dekker, Evelien, Verbeek, Wieke H. M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P. M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W. M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, and Snaebjornsson, Petur

Subjects
HODGKIN'S disease, ADENOMATOUS polyps, TUMORS, LOGISTIC regression analysis, CLINICAL pathology, DNA mismatch repair, BREAST cancer prognosis, PROGRESSION-free survival
Abstract

Background: Hodgkin's lymphoma (HL) survivors treated with abdominal radiotherapy and/or procarbazine have an increased risk of developing colorectal neoplasia. Aims: We evaluated the clinicopathological characteristics and risk factors for developing (advanced) neoplasia (AN) in HL survivors. Methods: In all, 101 HL survivors (median age 51 years, median age of HL diagnosis 25 years) underwent colonoscopy and 350 neoplasia and 44 AN (classified as advanced adenomas/serrated lesions or colorectal cancer), mostly right‐sided, were detected, as published previously. An average‐risk asymptomatic cohort who underwent screening colonoscopy were controls (median age 60 years). Clinicopathological characteristics of AN were evaluated in both groups. Mismatch repair (MMR) status was assessed using immunohistochemistry (MLH1/MSH2/MSH6/PMS2). Logistic regression analysis was performed to evaluate the risk factors for AN in HL survivors, including age at HL diagnosis and interval between HL and colonoscopy. Results: In 101 colonoscopies in HL survivors, AN was primarily classified based on polyp size ≥10 mm, whereas (high‐grade)dysplasia was more often seen in AN in controls. An interval between HL diagnosis and colonoscopy >26 years was associated with more AN compared with an interval of <26 years, with an odds ratio for AN of 3.8 (95% confidence interval 1.4–9.1) (p < 0.01). All 39 AN that were assessed were MMR proficient. Conclusions: Colorectal neoplasia in HL survivors differ from average‐risk controls; classification AN was primarily based on polyp size (≥10 mm) in HL survivors. Longer follow‐up between HL diagnosis and colonoscopy was associated with a higher prevalence of AN in HL survivors. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

24. Double Umbilical Cord Blood Transplantation in High-Risk Hematological Patients : A Phase II Study Focusing on the Mechanism of Graft Predominance

Author

Kalin, Burak, Ter Borg, Mariëtte, Wijers, Rebecca, Somers, Judith A E, van der Holt, Bronno, van Bergen, Cornelis A M, Petersen, Eefke J, Kuball, Jurgen, Meijer, Ellen, Schaap, Nicolaas P M, Zeerleder, Sacha S, Broers, Annoek E, Braakman, Eric, Falkenburg, J H Frederik, Lamers, Cor H J, Cornelissen, Jan J, Kalin, Burak, Ter Borg, Mariëtte, Wijers, Rebecca, Somers, Judith A E, van der Holt, Bronno, van Bergen, Cornelis A M, Petersen, Eefke J, Kuball, Jurgen, Meijer, Ellen, Schaap, Nicolaas P M, Zeerleder, Sacha S, Broers, Annoek E, Braakman, Eric, Falkenburg, J H Frederik, Lamers, Cor H J, and Cornelissen, Jan J

Published
2019

25. High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors

Author

Rigter, Lisanne S., Spaander, Manon C.W., Aleman, Berthe M.P., Bisseling, Tanya M., Moons, Leon M., Cats, Annemieke, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Snaebjornsson, Petur, Kuipers, Ernst J., Bruno, Marco J., Dekker, Evelien, Meijer, Gerrit A., de Boer, Jan Paul, van Leeuwen, Flora E., van Leerdam, Monique E., Rigter, Lisanne S., Spaander, Manon C.W., Aleman, Berthe M.P., Bisseling, Tanya M., Moons, Leon M., Cats, Annemieke, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Snaebjornsson, Petur, Kuipers, Ernst J., Bruno, Marco J., Dekker, Evelien, Meijer, Gerrit A., de Boer, Jan Paul, van Leeuwen, Flora E., and van Leerdam, Monique E.

Published
2019

26. Double Umbilical Cord Blood Transplantation in High-Risk Hematological Patients: A Phase II Study Focusing on the Mechanism of Graft Predominance

Author

MS Hematologie, Regenerative Medicine and Stem Cells, Cancer, CTI Kuball, Infection & Immunity, Kalin, Burak, Ter Borg, Mariëtte, Wijers, Rebecca, Somers, Judith A E, van der Holt, Bronno, van Bergen, Cornelis A M, Petersen, Eefke J, Kuball, Jurgen, Meijer, Ellen, Schaap, Nicolaas P M, Zeerleder, Sacha S, Broers, Annoek E, Braakman, Eric, Falkenburg, J H Frederik, Lamers, Cor H J, Cornelissen, Jan J, MS Hematologie, Regenerative Medicine and Stem Cells, Cancer, CTI Kuball, Infection & Immunity, Kalin, Burak, Ter Borg, Mariëtte, Wijers, Rebecca, Somers, Judith A E, van der Holt, Bronno, van Bergen, Cornelis A M, Petersen, Eefke J, Kuball, Jurgen, Meijer, Ellen, Schaap, Nicolaas P M, Zeerleder, Sacha S, Broers, Annoek E, Braakman, Eric, Falkenburg, J H Frederik, Lamers, Cor H J, and Cornelissen, Jan J

Published
2019

27. High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors

Author

MS MDL 1, Circulatory Health, MS Radiotherapie, Rigter, Lisanne S., Spaander, Manon C.W., Aleman, Berthe M.P., Bisseling, Tanya M., Moons, Leon M., Cats, Annemieke, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Snaebjornsson, Petur, Kuipers, Ernst J., Bruno, Marco J., Dekker, Evelien, Meijer, Gerrit A., de Boer, Jan Paul, van Leeuwen, Flora E., van Leerdam, Monique E., MS MDL 1, Circulatory Health, MS Radiotherapie, Rigter, Lisanne S., Spaander, Manon C.W., Aleman, Berthe M.P., Bisseling, Tanya M., Moons, Leon M., Cats, Annemieke, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Snaebjornsson, Petur, Kuipers, Ernst J., Bruno, Marco J., Dekker, Evelien, Meijer, Gerrit A., de Boer, Jan Paul, van Leeuwen, Flora E., and van Leerdam, Monique E.

Published
2019

30. Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients.

Author

Vries, Simone de, Schaapveld, Michael, Janus, Cécile P M, Daniëls, Laurien A, Petersen, Eefke J, Maazen, Richard W M van der, Zijlstra, Josée M, Beijert, Max, Nijziel, Marten R, Verschueren, Karijn M S, Kremer, Leontien C M, Eggermond, Anna M van, Lugtenburg, Pieternella J, Krol, Augustinus D G, Roesink, Judith M, Plattel, Wouter J, Spronsen, Dick Johan van, Imhoff, Gustaaf W van, Boer, Jan Paul de, and Aleman, Berthe M P

Subjects
HODGKIN'S disease, CARDIOVASCULAR disease related mortality, DEATH rate, MORTALITY, SPLEEN, CAUSES of death, RESEARCH, RESEARCH methodology, CANCER relapse, EVALUATION research, COMPARATIVE studies, SECONDARY primary cancer, LONGITUDINAL method
Abstract

Background: Few studies have examined the impact of treatment-related morbidity on long-term, cause-specific mortality in Hodgkin lymphoma (HL) patients.Methods: This multicenter cohort included 4919 HL patients, treated before age 51 years between 1965 and 2000, with a median follow-up of 20.2 years. Standardized mortality ratios, absolute excess mortality (AEM) per 10 000 person-years, and cause-specific cumulative mortality by stage and primary treatment, accounting for competing risks, were calculated.Results: HL patients experienced a 5.1-fold (AEM = 123 excess deaths per 10 000 person-years) higher risk of death due to causes other than HL. This risk remained increased in 40-year survivors (standardized mortality ratio = 5.2, 95% confidence interval [CI] = 4.2 to 6.5, AEM = 619). At age 54 years, HL survivors experienced similar cumulative mortality (20.0%) from causes other than HL to 71-year-old individuals from the general population. Whereas HL mortality statistically significantly decreased over the calendar period (P < .001), solid tumor mortality did not change in the most recent treatment era. Patients treated in 1989-2000 had lower 25-year cardiovascular disease mortality than patients treated in 1965-1976 (4.3% vs 5.7%; subdistribution hazard ratio = 0.65, 95% CI = 0.46 to 0.93). Infectious disease mortality was not only increased after splenectomy but also after spleen irradiation (hazard ratio = 2.81, 95% CI = 1.55 to 5.07). For stage I-II, primary treatment with chemotherapy (CT) alone was associated with statistically significantly higher HL mortality (P < .001 for CT vs radiotherapy [RT]; P = .04 for CT vs RT+CT) but lower 30-year mortality from causes other than HL (15.8%, 95% CI = 9.7% to 23.3%) compared with RT alone (36.9%, 95% CI = 34.0% to 39.8%, P = .001) and RT and CT combined (29.8%, 95% CI = 26.8% to 32.9%, P = .02).Conclusions: Compared with the general population, HL survivors have a substantially reduced life expectancy. Optimal selection of patients for primary CT is crucial, weighing risks of HL relapse and long-term toxicity. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

31. Impact of Donor-Derived CD34+ Infused Cell Dose on Outcomes of Patients Undergoing Allo-HCT Following Reduced Intensity Regimen for Myelofibrosis:a Study from the Chronic Malignancies Working Party of the EBMT

Author

Czerw, Tomasz, primary, Malpassuti, Vittoria, additional, Iacobelli, Simona, additional, Koster, Linda, additional, Kröger, Nicolaus, additional, Robin, Marie, additional, Maertens, Johan, additional, Chevallier, Patrice, additional, Mielke, Stephan, additional, Poire, Xavier, additional, Snowden, John A, additional, Petersen, Eefke J., additional, Malladi, Ram, additional, Blaise, Didier, additional, Reményi, Péter, additional, Gandemer, Virginie, additional, Cammenga, Jörg, additional, Rubio, Marie Thérèse, additional, Maury, Sébastien, additional, Deconinck, Eric, additional, Finnegan, Damian, additional, Hayden, Patrick, additional, Hernandez Boluda, Juan Carlos, additional, McLornan, Donal P., additional, and Yakoub-Agha, Ibrahim, additional

Published
2019
Full Text
View/download PDF

32. Double Umbilical Cord Blood Transplantation in High‐Risk Hematological Patients: A Phase II Study Focusing on the Mechanism of Graft Predominance

Author

Kalin, Burak, primary, ter Borg, Mariëtte, additional, Wijers, Rebecca, additional, Somers, Judith A.E., additional, van der Holt, Bronno, additional, van Bergen, Cornelis A.M., additional, Petersen, Eefke J., additional, Kuball, Jurgen, additional, Meijer, Ellen, additional, Schaap, Nicolaas P.M., additional, Zeerleder, Sacha S., additional, Broers, Annoek E., additional, Braakman, Eric, additional, Falkenburg, J.H. Frederik, additional, Lamers, Cor H.J., additional, and Cornelissen, Jan J., additional

Published
2019
Full Text
View/download PDF

33. High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors

Author

Rigter, Lisanne S., primary, Spaander, Manon C. W., additional, Aleman, Berthe M. P., additional, Bisseling, Tanya M., additional, Moons, Leon M., additional, Cats, Annemieke, additional, Lugtenburg, Pieternella J., additional, Janus, Cecile P. M., additional, Petersen, Eefke J., additional, Roesink, Judith M., additional, van der Maazen, Richard W. M., additional, Snaebjornsson, Petur, additional, Kuipers, Ernst J., additional, Bruno, Marco J., additional, Dekker, Evelien, additional, Meijer, Gerrit A., additional, de Boer, Jan Paul, additional, van Leeuwen, Flora E., additional, and van Leerdam, Monique E., additional

Published
2018
Full Text
View/download PDF

35. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis

Author

Admiraal, Rick, Nierkens, Stefan, de Witte, Moniek A, Petersen, Eefke J, Fleurke, Ger-Jan, Verrest, Luka, Belitser, S., Bredius, Robbert G M, Raymakers, Reinier A P, Knibbe, Catherijne A J, Minnema, Monique C, Van Kesteren, Charlotte, Kuball, Jurgen, Boelens, Jaap J, Sub Pharmacotherapy, Theoretical, and Pharmacoepidemiology and Clinical Pharmacology

Abstract

BACKGROUND: Anti-thymocyte globulin (ATG) is used to prevent graft-versus-host disease (GvHD) after allogeneic haemopoietic cell transplantation (HCT). However, ATG can also cause delayed immune reconstitution of T cells, negatively affecting survival. We studied the relation between exposure to ATG and clinical outcomes in adult patients with acute leukaemia and myelodysplastic syndrome. METHODS: We did a retrospective, pharmacokinetic-pharmacodynamic analysis of data from patients with acute lymphoid leukaemia, acute myeloid leukaemia, or myelodysplastic syndrome receiving their first T-cell repleted allogeneic peripheral blood stem cell HCT with ATG (thymoglobulin) as part of non-myeloablative conditioning from March 1, 2004, to June 1, 2015. Patients received a cumulative intravenous dose of 8 mg/kg divided over 4 days, starting on day -8 before HCT. Active ATG concentrations were measured using a validated bioassay and pharmacokinetic exposure measures (maximum concentration, concentration at time of infusion of the graft, time to reach a concentration of 1 arbitary unit [AU] per day/mL, area under the curve [AUC], and the AUC before and after HCT) were calculated with a validated population pharmacokinetic model. The main outcome of interest was 5-year overall survival, defined as days to death from any cause or last follow-up. Other outcomes were relapse-related mortality, non-relapse mortality, event-free survival, acute and chronic GvHD, and assessment of current and optimum dosing. We used Cox proportional hazard models and Fine-Gray competing risk models for the analyses. FINDINGS: 146 patients were included. ATG exposure after HCT was shown to be the best predictor for 5-year overall survival. Optimum exposure after transplantation was determined to be 60-95 AU per day/mL. Estimated 5-year overall survival in the group who had optimum exposure (69%, 95% CI 55-86) was significantly higher than in the group who had below optimum exposure (32%, 20-51, p=0·00037; hazard ratio [HR] 2·41, 95% CI 1·15-5·06, p=0·020) and above optimum exposure (48%, 37-62, p=0·030; HR 2·11, 95% CI 1·04-4·27, p=0·038). Patients in the optimum exposure group had a greater chance of event-free survival than those in the below optimum exposure group (HR 2·54, 95% CI 1·29-5·00, p=0·007; HR for the above optimum group: 1·83, 0·97-3·47, p=0·063). Above-optimum exposure led to higher relapse-related mortality compared with optimum exposure (HR 2·66, 95% CI 1·12-6·31; p=0·027). Below optimum exposure increased non-relapse mortality compared with optimum exposure (HR 4·36, 95% CI 1·60-11·88; p=0·0040), grade 3-4 acute GvHD (3·09, 1·12-8·53; p=0·029), but not chronic GvHD (2·38, 0·93-6·08; p=0·070). Modelled dosing based on absolute lymphocyte counts led to higher optimum target attainment than did weight-based dosing. INTERPRETATION: Exposure to ATG affects survival after HCT in adults, stressing the importance of optimum ATG dosing. Individualised dosing of ATG, based on lymphocyte counts rather than bodyweight, might improve survival chances after HCT. FUNDING: Netherlands Organization for Health Research and Development and Queen Wilhelma Fund for Cancer Research.

Published
2017

36. Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia: On Behalf of Eurocord, Ctiwp and PDWP of EBMT

Author

Hayashi, Hiromi, primary, Volt, Fernanda, additional, Sanz, Jaime, additional, Petersen, Eefke J., additional, Boissel, Nicolas, additional, Hough, Rachael, additional, Milpied, Noel, additional, Angelucci, Emanuele, additional, Yakoub-Agha, Ibrahim, additional, Michallet, Mauricette, additional, Michel, Gerard, additional, Aljurf, Mahmoud, additional, Kenzey, Chantal, additional, Rocha, Vanderson, additional, Dalle, Jean-Hugues, additional, Bader, Peter, additional, Gluckman, Eliane, additional, and Ruggeri, Annalisa, additional

Published
2018
Full Text
View/download PDF

37. Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma Improved Overall Survival in Upfront Hematopoietic Stem Cell Transplantation — a Large Retrospective Study By the Chronic Malignancies Working Party of the EBMT

Author

Gran, Charlotte, primary, Wang, Junfeng, additional, Nahi, Hareth, additional, Koster, Linda, additional, Gahrton, Goesta, additional, Wolschke, Christine, additional, Einsele, Hermann, additional, Itälä-Remes, Maija, additional, Blaise, Didier, additional, Niederwieser, Dietger, additional, Meijer, Ellen, additional, Petersen, Eefke J., additional, de Wreede, Liesbeth C., additional, Ljungman, Per, additional, Bourhis, Jean-Henri, additional, Veelken, Hendrik, additional, Beelen, Dietrich W., additional, Stelljes, Matthias, additional, Gerbitz, Armin, additional, Ceballos, Patrice, additional, Finke, Jürgen, additional, Passweg, Jakob R., additional, Milpied, Noel-Jean, additional, Bornhäuser, Martin, additional, Yakoub-Agha, Ibrahim, additional, Schönland, Stefan, additional, Garderet, Laurent, additional, and Kroeger, Nicolaus, additional

Published
2018
Full Text
View/download PDF

38. Outcomes after Unrelated Cord Blood Transplantation (UCBT) in Patients with Chronic Myeloid Leukemia (CML): A Retrospective Study from the Cmwp-EBMT

Author

De Lavallade, Hugues, primary, Sbianchi, Giulia, additional, Koster, Linda, additional, Sanz, Jaime, additional, Angelucci, Emanuele, additional, Socie, Gerard, additional, Pietri, Isabelle, additional, Labussière-Wallet, Hélène, additional, Cornelissen, Jan J, additional, Gedde-Dahl, Tobias, additional, Petersen, Eefke J., additional, Bonifazi, Francesca, additional, Sierra, Jorge, additional, Carre, Martin, additional, Marchand, Tony, additional, Pochon, Cecile, additional, Russel, Nigel H, additional, Potter, Victoria, additional, Sengeloev, Henrik, additional, Ljungman, Per, additional, Lapusan, Simona, additional, Blaise, Didier, additional, Iori, Anna Paola, additional, Ruggeri, Annalisa, additional, Chalandon, Yves, additional, and Yakoub-Agha, Ibrahim, additional

Published
2018
Full Text
View/download PDF

39. Results of Autologous and Allogeneic Transplantation in Patients with Primary Plasma Cell Leukemia: A Large Retrospective Analysis of the Chronic Malignancies Working Party of the EBMT

Author

Lawless, Sarah, primary, Iacobelli, Simona, additional, Knelange, Nina, additional, Chevallier, Patrice, additional, Blaise, Didier, additional, Milpied, Noel-Jean, additional, Foà, Robin, additional, Cornelissen, Jan J, additional, Lioure, Bruno, additional, Potter, Victoria, additional, Poire, Xavier, additional, Petersen, Eefke J., additional, Collin, Matthew P., additional, Lenhoff, Stig, additional, Snowden, John, additional, Santarone, Stella, additional, Wilson, Keith, additional, Guimaraes, Jose E., additional, Dreger, Peter, additional, Schipperus, Martin R., additional, Morris, Curly, additional, Schönland, Stefan, additional, Yakoub-Agha, Ibrahim, additional, Garderet, Laurent, additional, and Nicolaus, Kroger, additional

Published
2018
Full Text
View/download PDF

40. The Optimal Alternative Donor Transplant for Pediatric Patients with Acute Leukemia: A Comparison between Alfa-Beta T-Cell and B-Cell Depleted Haplo-SCT and UCBT

Author

Locatelli, Franco, primary, Labopin, Myriam, additional, Santoro, Nicole, additional, Dalle, Jean-Hugues, additional, Al-Seraihy, Amal, additional, Volt, Fernanda, additional, Maschan, Mikhail, additional, Jubert, Charlotte, additional, Zecca, Marco, additional, Petersen, Eefke J., additional, Díaz Pérez, Miguel Ángel, additional, Michel, Gerard, additional, Skorobogatova, Elena, additional, Díaz de Heredia, Cristina, additional, OBrien, Tracey, additional, Kenzey, Chantal, additional, Rocha, Vanderson, additional, Gluckman, Eliane, additional, Bader, Peter, additional, and Ruggeri, Annalisa, additional

Published
2018
Full Text
View/download PDF

41. First Results of a Prospective I/II Clinical Trial in Adult Patients Using TCR Alpha/Beta Depleted Stem Cell Transplantation from Matched Related and Unrelated Donors

Author

De Witte, Moniek, primary, Rhenen, Anna Van, additional, Van Sluis, Geerte, additional, Admiraal, Rick, additional, van der Wagen, Lotte, additional, Petersen, Eefke J., additional, Raymakers, Reinier, additional, Minnema, Monique C, additional, Janssen, Anke, additional, Westinga, Kasper, additional, Halkes, Constantijn J.M., additional, Falkenburg, J.H. Frederik, additional, Boelens, Jaap Jan, additional, and Kuball, Jurgen, additional

Published
2018
Full Text
View/download PDF

42. Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer : study design

Author

Rigter, Lisanne S, Spaander, Manon C W, Moons, Leon M, Bisseling, Tanya M, Aleman, Berthe M P, de Boer, Jan Paul, Lugtenburg, Pieternella J, Janus, Cecile P M, Petersen, Eefke J, Roesink, Judith M, Raemaekers, John M M, van der Maazen, Richard W M, Cats, Annemieke, Bleiker, Eveline M A, Snaebjornsson, Petur, Carvalho, Beatriz, Lansdorp-Vogelaar, Iris, Jóźwiak, Katarzyna, Te Riele, Hein, Meijer, Gerrit A, van Leeuwen, Flora E, van Leerdam, Monique E, Rigter, Lisanne S, Spaander, Manon C W, Moons, Leon M, Bisseling, Tanya M, Aleman, Berthe M P, de Boer, Jan Paul, Lugtenburg, Pieternella J, Janus, Cecile P M, Petersen, Eefke J, Roesink, Judith M, Raemaekers, John M M, van der Maazen, Richard W M, Cats, Annemieke, Bleiker, Eveline M A, Snaebjornsson, Petur, Carvalho, Beatriz, Lansdorp-Vogelaar, Iris, Jóźwiak, Katarzyna, Te Riele, Hein, Meijer, Gerrit A, van Leeuwen, Flora E, and van Leerdam, Monique E

Published
2017

43. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis

Author

Sub Pharmacotherapy, Theoretical, Pharmacoepidemiology and Clinical Pharmacology, Admiraal, Rick, Nierkens, Stefan, de Witte, Moniek A, Petersen, Eefke J, Fleurke, Ger-Jan, Verrest, Luka, Belitser, S., Bredius, Robbert G M, Raymakers, Reinier A P, Knibbe, Catherijne A J, Minnema, Monique C, Van Kesteren, Charlotte, Kuball, Jurgen, Boelens, Jaap J, Sub Pharmacotherapy, Theoretical, Pharmacoepidemiology and Clinical Pharmacology, Admiraal, Rick, Nierkens, Stefan, de Witte, Moniek A, Petersen, Eefke J, Fleurke, Ger-Jan, Verrest, Luka, Belitser, S., Bredius, Robbert G M, Raymakers, Reinier A P, Knibbe, Catherijne A J, Minnema, Monique C, Van Kesteren, Charlotte, Kuball, Jurgen, and Boelens, Jaap J

Published
2017

44. Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design

Author

MS MDL Oncologie, Cancer, MS MDL 1, Regenerative Medicine and Stem Cells, MS Hematologie, MS Radiotherapie, Rigter, Lisanne S, Spaander, Manon C W, Moons, Leon M, Bisseling, Tanya M, Aleman, Berthe M P, de Boer, Jan Paul, Lugtenburg, Pieternella J, Janus, Cecile P M, Petersen, Eefke J, Roesink, Judith M, Raemaekers, John M M, van der Maazen, Richard W M, Cats, Annemieke, Bleiker, Eveline M A, Snaebjornsson, Petur, Carvalho, Beatriz, Lansdorp-Vogelaar, Iris, Jóźwiak, Katarzyna, Te Riele, Hein, Meijer, Gerrit A, van Leeuwen, Flora E, van Leerdam, Monique E, MS MDL Oncologie, Cancer, MS MDL 1, Regenerative Medicine and Stem Cells, MS Hematologie, MS Radiotherapie, Rigter, Lisanne S, Spaander, Manon C W, Moons, Leon M, Bisseling, Tanya M, Aleman, Berthe M P, de Boer, Jan Paul, Lugtenburg, Pieternella J, Janus, Cecile P M, Petersen, Eefke J, Roesink, Judith M, Raemaekers, John M M, van der Maazen, Richard W M, Cats, Annemieke, Bleiker, Eveline M A, Snaebjornsson, Petur, Carvalho, Beatriz, Lansdorp-Vogelaar, Iris, Jóźwiak, Katarzyna, Te Riele, Hein, Meijer, Gerrit A, van Leeuwen, Flora E, and van Leerdam, Monique E

Published
2017

46. Attendance to Hodgkin lymphoma survivorship care clinics in the Netherlands.

Author

Nijdam, Annelies, primary, de Weijer, Roel J., additional, Janus, Cecile P.M., additional, Clevers-Petersen, Eefke J., additional, Roesink, Judith M., additional, Lugtenburg, Pieternella J., additional, van 't Veer, Mars B., additional, Aleman, Berthe M.P., additional, Raemaekers, John M. M., additional, and Van Leeuwen, Flora, additional

Published
2017
Full Text
View/download PDF

47. Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design

Author

Rigter, Lisanne S., primary, Spaander, Manon C. W., additional, Moons, Leon M., additional, Bisseling, Tanya M., additional, Aleman, Berthe M. P., additional, de Boer, Jan Paul, additional, Lugtenburg, Pieternella J., additional, Janus, Cecile P. M., additional, Petersen, Eefke J., additional, Roesink, Judith M., additional, Raemaekers, John M. M., additional, van der Maazen, Richard W. M., additional, Cats, Annemieke, additional, Bleiker, Eveline M. A., additional, Snaebjornsson, Petur, additional, Carvalho, Beatriz, additional, Lansdorp-Vogelaar, Iris, additional, Jóźwiak, Katarzyna, additional, te Riele, Hein, additional, Meijer, Gerrit A., additional, van Leeuwen, Flora E., additional, and van Leerdam, Monique E., additional

Published
2017
Full Text
View/download PDF

48. Long-Term Follow-up Data Support the Curative Potential of Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis from the Chronic Malignancies Working Party of the EBMT

Author

Van Gelder, Michel, primary, de Wreede, Liesbeth, additional, Henseler, Anja, additional, van Biezen, Anja, additional, Niederwieser, Dietger, additional, Karas, Michal, additional, Andersen, Niels S., additional, Gramatzki, Martin, additional, Dreger, Peter, additional, Bunjes, Donald W., additional, Petersen, Eefke J, additional, Potter, Michael N, additional, Beelen, Dietrich, additional, Yakoub-Agha, Ibrahim, additional, Cornelissen, Jan J, additional, Russell, Nigel, additional, Finke, Jurgen, additional, Schoemans, Helene, additional, Blaise, Didier, additional, Shankara, Paneesha, additional, Vitek, Antonin, additional, Bornhäuser, Martin, additional, Schönland, Stefan, additional, Kröger, Nicolaus, additional, and Schetelig, Johannes, additional

Published
2014
Full Text
View/download PDF

49. Double Cord Blood Transplantation: Incidence, Organ Involvement and Risk Factors of Acute Graft Versus Host Disease. a Retrospective Analysis on Behalf of Eurocord, ALWP and Cqwp-EBMT

Author

Xavier, Erick, primary, Ruggeri, Annalisa, additional, Labopin, Myriam, additional, Blaise, Didier, additional, Chevallier, Patrice, additional, Fegueux, Nathalie, additional, Cornelissen, Jan J., additional, Deconinck, Eric, additional, Michallet, Mauricette, additional, Socie, Gerard, additional, Mohty, Mohamad, additional, Sengeloev, Henrik, additional, Karakasis, Dimitrios, additional, Mannone, Lionel, additional, Milpied, Noel, additional, Nagler, Arnon, additional, Maillard, Natacha, additional, Clement, Laurence, additional, Cahn, Jean-Yves, additional, Bay, Jacques-Olivier, additional, Lamy, Thierry, additional, Petersen, Eefke J, additional, McQuaker, Grant, additional, Craddock, Charles, additional, Bourhis, Jean-Henri, additional, Tischer, Johanna, additional, Kenzey, Chantal, additional, Volt, Fernanda, additional, Giannotti, Federica, additional, Gluckman, Eliane, additional, Duarte, Rafael F., additional, and Rocha, Vanderson, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results